TVTX
NASDAQ HealthcareTravere Therapeutics, Inc. - Common Stock
Biotechnology
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
�� 市场数据
| 价格 | $40.77 |
|---|---|
| 成交量 | 1,922,617 |
| 市值 | 3.77B |
| 贝塔系数 | 0.870 |
| RSI（14日） | 75.6 超买 |
| 200日均线 | $27.52 |
| 50日均线 | $30.01 |
| 52周最高 | $43.31 |
| 52周最低 | $13.88 |
| Forward P/E | 8.94 |
| Price / Book | 32.28 |
🎯 投资策略评分
TVTX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (59/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🔪 Falling Knife (10/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 TVTX in your text
粘贴任何文章、记录或帖子 — 工具将提取 TVTX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.